What question did this study set out to answer?

The aim is to develop patient-derived organoid and xenograft models to evaluate drug responses in ovarian cancer.

Developing Patient-Derived Organoid and Xenograft Models for Ovarian Cancer Assessment

View Full Paper

Ask AI

Bookmark

The aim is to develop patient-derived organoid and xenograft models to evaluate drug responses in ovarian cancer.
Collected tumor tissue from multiple sites during surgery
Cultured patient-derived organoids in basement membrane extract
Injected cells into immunodeficient mice to create xenograft models
Conducted drug screening with 14 different agents using viability assays
Monitored tumor growth to determine the time to reach 100 mm3
Established 18 PDOs from 14 advanced-stage ovarian cancer patients
Demonstrated variable drug response in screenings, especially to platinum-based drugs and PARP inhibitors
Successfully developed PDX models in 26.5% of patients, showing shorter growth times in intrabursal models
Noted accelerated tumor formation with successive passages, indicating improved growth kinetics

No takes yet. Share an insight, caveat, or question.

Develops organoid and xenograft models to assess drug responses in ovarian cancer, suggesting potential for precision medicine.

Lee et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark